Boston Scientific (BSX): Down 57% While Revenue Grew — Q2 2026

Boston Scientific Corporation (BSX) Q2 2026 — Net sales were $5.442B, +7.5% reported and +7.0% organic, at the TOP of a 5.5-7.5% guide. Adjusted EPS was $0.86 against a $0.82-$0.84 guide and $0.75 a year ago; GAAP EPS was $0.61 vs $0.53. Adjusted operating margin reached 28.4%, up 71bps. Cardiovascular grew +7.8% organic to $3,624M and MedSurg +5.4% to $1,818M. Yet management cut full-year guidance for the second time in six months, to 5.0-6.0% organic and $3.28-$3.32 adjusted EPS, and guided Q3 to just 3-5%. The stock closed at $46.00, about 57% below its September 2025 closing high of $108.14. The quarter beat on both lines and the stock has still halved in eleven months — the market is repricing the story, not the earnings. Three things almost nobody has put together. (1) The second-half cliff: FY2025 revenue was $20.074B and the new guide implies $21.18-$21.38B; H1 2026 was already $10.646B, so H2 must land at $10.53-$10.73B against H2 2025's $10.350B — implied growth of just +1.8% to +3.7%, versus +9.5% in H1. Organic guidance has gone 10-11% to 6.5-8.0% to 5.0-6.0% since February, and sequential organic growth ran 9.4%, then 7.0%, with Q3 guided to 3-5%. (2) Why: CHAMPION-AF (NEJM, March 28) was meant to make WATCHMAN first-line versus blood thinners. It met every endpoint but won only on bleeding (10.9% vs 19.0%) and merely tied on efficacy (5.7% vs 4.8%), with more primary events in the device arm (81 vs 65) and more ischaemic strokes (45 vs 27) — a label filing, not a guideline change. (3) Capital allocation: ~$16B committed into the deceleration. One overlooked twist — the Penumbra exchange ratio is FIXED at 3.8721 BSX shares, struck off an implied ~$96.59 price, so at $46 the blended consideration is ~$321/share, not $374. Penumbra closed at $319.83. THE CALL: BUY (3/5, THE DE-RATING WENT FURTHER THAN THE DOWNGRADE) — base-case value ~$54.0 vs ~$46.0 today. KEY METRICS: - Revenue $5.442B, +7.5% reported / +7.0% organic, at the top of a 5.5-7.5% guide - Adjusted EPS $0.86 vs a $0.82-$0.84 guide and $0.75 a year ago (+14.7%); GAAP EPS $0.61 vs $0.53 - Adjusted gross margin 70.3% (vs 69.4%); adjusted operating margin 28.4% (vs 27.6%), +71bps - Cardiovascular $3,624M +7.8% organic; MedSurg $1,818M +5.4% (Endoscopy +7.0%, Neuromodulation +12.2%, Urology just +0.8%) - FY2026 guidance cut twice: 10.5-11.5%/10-11% and $3.43-$3.49 (Feb 4) to 7.0-8.5%/6.5-8.0% and $3.34-$3.41 (Apr 22) to 5.5-6.5%/5.0-6.0% and $3.28-$3.32 (Jul 29) - The implied H2 cliff: H1 grew +9.5%, but the full-year guide requires H2 growth of only +1.8% to +3.7% - CHAMPION-AF: superior on non-procedural bleeding (10.9% vs 19.0%) but non-inferior only on efficacy (5.7% vs 4.8%), with 81 primary events vs 65 and 45 ischaemic strokes vs 27 - Penumbra: $14.5B, ~73% cash, fixed 3.8721 exchange ratio; blended value now ~$321/share vs the $374 headline (PEN closed $319.83) - MiRus: $1.5B for ~34% plus a $3B option on an investigational TAVR valve — a market BSX exited in May 2025 when ACURATE missed its endpoint - New 2026 Restructuring Plan: $700-800M of charges to remove ~$500M of annual expense by 2029; $2B ASR completed (~40M shares), $3B left - Net debt ~$9.5B at March 31, ~$11.8B pro-forma for the buyback and MiRus, and above $22B once Penumbra closes - FY2025 free cash flow $3,658M (operating cash flow $4,534M less $876M capex, per the 10-K) - At $46.00: 13.9x the $3.30 midpoint of FY2026 adjusted EPS guidance and a ~5.9% free cash flow yield — cheaper than Medtronic, which grows slower What to watch: Watch Q3: management guided 3-5% organic and has beaten its own guide twice running — a 6%+ print breaks the deceleration narrative. The other levers are $500M of restructuring savings and closing Penumbra (~$1.4B of revenue growing ~17%). What breaks it: a badly integrated Penumbra, net debt settling above $22B with no deleveraging path, or evidence that the post-CHAMPION-AF debate is actively reducing WATCHMAN procedure volumes rather than merely failing to expand them. Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.